Form 8-K - Current report:
SEC Accession No. 0001104659-25-008146
Filing Date
2025-01-31
Accepted
2025-01-31 16:39:24
Documents
15
Period of Report
2025-01-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm254911d1_8k.htm   iXBRL 8-K 41105
2 EXHIBIT 10.1 tm254911d1_ex10-1.htm EX-10.1 136854
3 EXHIBIT 10.2 tm254911d1_ex10-2.htm EX-10.2 66515
  Complete submission text file 0001104659-25-008146.txt   477591

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA otlk-20250130.xsd EX-101.SCH 3048
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20250130_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20250130_pre.xml EX-101.PRE 22381
17 EXTRACTED XBRL INSTANCE DOCUMENT tm254911d1_8k_htm.xml XML 3656
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 25578943
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)